BillionToOne Analyst Price Targets - Benzinga

BillionToOne Inc

BLLNNASDAQ

Trade with Public

Trade with Public

$114.42

-1.65-1.42%

À la clôture: Sep 23, 5:00 PM EST

$115.00

0.580.51%

Après les heures: 5:35 PM EST

Aperçu Actualités Prévisions de résultats ÉvénementsObjectifs de coursDonnées financières Sentiment Actionnariat Comparer Options Rapport sur les stocks

BillionToOne Analyst Price Targets

Wall Street analyst price targets and consensus rating for BillionToOne (BLLN).

Price Target Range — 4 Quarters

Analyst Consensus — 7 Analysts

6Buy

1Hold

Consensus RatingBuy# Analysts7Avg. Consensus PT$126Upside to Avg. PT+9.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 2, 2026	Canaccord Genuity	Kyle Mikson	Initiate	Buy	$120
Aug 6, 2026	JP Morgan	Casey Woodring	PT Cut	Overweight	$145→$130
Aug 6, 2026	BTIG	Mark Massaro	PT Cut	Buy	$142→$130
Jun 29, 2026	Guggenheim	Subbu Nambi	Initiate	Buy	$120→$125
May 13, 2026	Guggenheim	Subbu Nambi	PT Raise	Buy	$100→$120
May 7, 2026	JP Morgan	Casey Woodring	PT Raise	Overweight	$120→$125
May 7, 2026	BTIG	Mark Massaro	PT Cut	Buy	$140→$130
Mar 30, 2026	Guggenheim	Subbu Nambi	PT Cut	Buy	$120→$100
Mar 5, 2026	Wells Fargo	Brandon Couillard	PT Cut	Equal-Weight	$110→$90
Mar 5, 2026	Guggenheim	Subbu Nambi	Maintained	Buy	$120
Mar 5, 2026	BTIG	Mark Massaro	PT Cut	Buy	$160→$140
Dec 10, 2025	JP Morgan	Casey Woodring	PT Cut	Overweight	$150→$145
Dec 10, 2025	BTIG	Mark Massaro	Maintained	Buy	$160
Dec 1, 2025	Piper Sandler	David Westenberg	Initiate	Overweight	$150
Dec 1, 2025	Stifel	Daniel Arias	Initiate	Buy	$145
Dec 1, 2025	Wells Fargo	Brandon Couillard	Initiate	Equal-Weight	$110
Dec 1, 2025	JP Morgan	Casey Woodring	Initiate	Overweight	$150
Dec 1, 2025	Jefferies	Tycho Peterson	Initiate	Hold	$117
Dec 1, 2025	BTIG	Mark Massaro	Initiate	Buy	$160

More with Benzinga EdgeGet Access

Analyst Ratings News

Medicare Lab Fee Changes Impact BillionToOne, CareDx Differently

CMS aligns 2027 clinical lab fees with private payors to save $1 billion, yielding positive updates for CareDx and BillionToOne tests.

Vandana Singh

PRO
Canaccord Genuity Initiates Coverage On BillionToOne with Buy Rating, Announces Price Target of $120

Canaccord Genuity analyst Kyle Mikson initiates coverage on BillionToOne (NASDAQ:BLLN) with a Buy rating and announces Price Target of $120.

Benzinga Newsdesk

PRO
BTIG Maintains Buy on BillionToOne, Lowers Price Target to $130

BTIG analyst Mark Massaro maintains BillionToOne (NASDAQ:BLLN) with a Buy and lowers the price target from $142 to $130.

Benzinga Newsdesk

PRO
Guggenheim Initiates Coverage On BillionToOne with Buy Rating, Raises Price Target to $125

Guggenheim analyst Subbu Nambi initiates coverage on BillionToOne (NASDAQ:BLLN) with a Buy rating and raises Price Target to $125.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on BillionToOne, Raises Price Target to $120

Guggenheim analyst Subbu Nambi maintains BillionToOne (NASDAQ:BLLN) with a Buy and raises the price target from $100 to $120.

Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on BillionToOne, Raises Price Target to $125

JP Morgan analyst Casey Woodring maintains BillionToOne (NASDAQ:BLLN) with a Overweight and raises the price target from $120 to $125.

Benzinga Newsdesk